The rising importance of containment in small molecule drug development
Pharmaceutical Technology
DECEMBER 6, 2022
HPAPIs may now represent more than 30% of the drug development pipeline. Within that figure, GlobalData estimates that around 60% of pipeline HPAPIs are developed to target oncology. Cross-contamination of standard products with highly potent ones is another key concern. Prioritising safety in early-stage development.
Let's personalize your content